This site is part of the Informa Connect Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 3099067.

TIDES Asia: Oligonucleotide & Peptide Therapeutics Scientific Forum
See You Next Year! 26-28 Feb, 2025
Westin Miyako KyotoKyoto, Japan

Ying Tam, Ph.D.
Chief Scientific Officer at Acuitas Therapeutics


Dr. Tam obtained his M.Sc. and Ph.D. University of Waterloo, Canada. He has held several senior academic and industry positions including being one of the founding scientists of Acuitas Therapeutics in 2009. He is now Chief Scientific Officer at Acuitas, a company with a leadership position in the development and application of lipid nanoparticle (LNP) technology for delivery of nucleic acid therapeutics, in particular, messenger RNA therapeutics. Dr. Tam has over 100 publications in peer-reviewed journals relating to LNP technology and development of pharmaceutical products.

Agenda Sessions

  • Lipid Nanoparticles to Enable Clinical Development of mRNA-based Therapeutics